Even in AFP negative and PIVKA-II negative HCC patients, the performance of P4 panel remained effective, with AUC of 0.878 (HCC/LC) and 0.904 (HCC/HC) in the validation set (Fig. 6d, Supplementary Fig. 5g, h). Here, AFP is linked to hepatocellular carcinoma.